EMA starts rolling review for Eli Lilly's Covid-19 treatment

Two new antibodies for Covid-19 have been placed under rolling review by the EMA. This will ensure faster approval in case the drug reaches the point of submitting an application.


The European Medicines Agency (EMA) has started reviewing the preliminary data on two Eli Lilly treatments for Covid-19, writes the Danish Medicines Agency in a press announcement.

This will be in the form of a rolling review of the antibody bamlanivimab and a bamlanivimab-etesevimab combination.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs